Is Hologic, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Hologic, Inc. moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 21, an EV to EBITDA of 14.41, and a PEG ratio of 1.65. In comparison, Baxter International, Inc. has a higher P/E of 28.68, indicating a riskier valuation, while Align Technology, Inc. presents a more attractive P/E of 20.46.
Despite Hologic's recent stock performance showing a 3.08% return over the past week compared to the S&P 500's 1.70%, the longer-term outlook reveals a decline with a -13.20% return over the past year versus the S&P 500's 14.08%. This suggests that while Hologic is currently fairly valued, its recent performance may raise concerns for investors.